Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Should have some COPD results from after next week, looking forward to seeing them.
We can agree on most things accept maybe the dosing levels .....
Thanks, SGD27 !
Interesting article, thanks for posting.
Again, the emphasis seems to be on timing and dosage, as to the effectiveness and safety of interferon treatment. The method of delivery is also going to be key.
I think we can assume that the safety aspect of Sng is fairly robust given that it has been authorised for the home trial. Clearly in the home setting at least, it is also being administered to patients as early as is reasonable practical.
So I would suggest those two key areas can be given a tick in the sng trial.
Which leaves the last consideration, dosage. Synairgen will have been assessing this issue for a number of years and must have a very precise idea of the level of dosage they can administer via nebuliser that would have real effect.
So I see that article as generally supportive of what sng might be able to achieve here. It does refer to the individual’s response to interferon, and possible side effects, and this appears to be in line with what Synaifgen state in their consent form for the trials.
https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-1170-4395.pdf
I reckon there's gonna be a few surprises along the way, will certainly catch out a few who think they're gonna jump back in easy prior to results.
@phoenix41 : Thanks for the links. Hint - use lower case "https" to get them to work properly :-)
https://onenucleus.com/transcrip-providing-support-synairgen-confirms-commencement-dosing-trial-sng001-covid-19
Seems a bit inconclusive. Synairgen can fill in the blanks when they get the results.
High dose intravenous can have some side effects especially around the injection site.. Not the same application as SNG001 which is via nebulizer and as far as I know has not been reported as high dose just that its a formulation...
TranScrip seem to have been involved in the logistics etc of setting this all up with SNG ( see first link - OneNucleus ).
The other link from Transcrip, I found interesting in terms of gleaning some info on the challenges of CV19 trials and data interpretation from them. Thought it was worth sharing ?
hTTps://onenucleus.com/transcrip-providing-support-synairgen-confirms-commencement-dosing-trial-sng001-covid-19
hTTps://www.transcrip-partners.com/news/covid-19-developing-drugs-and-biological-products-treatment-or-prevention-background-and-new
Congratulations Ghia :-) ......By far the best thing you can ever achieve is have a child and a lovely thought regarding your father-in-law. My 3 still make me proud of how they've grown ! If SNG proves to be the winner we all hope we have, at least I can set them up with handsome house deposits to get them started. Then I will be opening a very special cognac to toast everyone involved :-)
Well well well
https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1170-4395?device=mobile&innerWidth=980&offsetWidth=980
Goose - I have a bottle of single malt left to me by my late father in law. Expecting our first child in a few months so that combined potential success with Synairgen seems like a fitting time to have a sample and toast his memory.
So I like to view it as everyday is one day closer to the malt!
Ghia ......we certainly are closer to the finish than the start :-) positive in itself......
Still around, don't worry ;-)
Nolupus - I think everyone is having a bit of a breather, should get a bit more interesting in a couple of weeks.
The only issue is if SNG001 works or not. Nothing to debate really as we can now only wait for the results.
Tick..
Tock...
Nobody to debate real issues ??
So my main questions for these Covid trials are as follows
Are the dosage levels ( the same as COPD ) sufficient to boost against covid 19
Will the timing of dosage be optimal ?
Have they tested the patients interferon signature ? How many high versus low ?
Is interferon beta 1a. More effective than other types of interferon such as Alpha 2b in covid patients ?
And finally, is our system more effective than IV or SC
The number of patients tested for the home trial (120-300 ) ?? vs hospital (100)
Lot's of questions but will have to wait for the Results for many of the answers
DATA is KING
Coming back to SNG ...
Autoimmune diseases are becoming more and more frequent and interferons are believed to be one of the major factors involved in autoimmune problems .
We are not all equal in relation to autoimmune diseases ....that is why some people have a deficiency of some interferons whilst others have too many
In preventative medicine we should all be tested for our interferon signature and that brings me back to Sng ...
Fine tuning the immune system , dosing levels and timing of dosage ...
Now , science will probably show that we need to balance out the immune system at all stages of the covid 19 ...
We may need to boost the interferons in certain patients and limit them in others ...
That is why these clinical trials are so important , theories have to be backed up by the data ...
you dont just get OTC approval until the drug is deemed idiot proof and safe until then it will be strictly doctor/hospital only
Thanks Nolupus. I see this as a treatment one would buy in the chemist much like you would buying medication for cold/flu. Anything easily accessible to avoid hospital visits that benefits/alleviates the symptoms can only be a good thing in my book.
From all that I have read , it is now been proven that we do indeed generate neutralizing antibodies after having had the covid 19., but it's too early to say how long they will last for ....Only time will tell
Nolupus...that's pretty scary stuff in the link you posted.
'Is it possible that some of the extensive organ, tissue, and cellular damage done by SARS-CoV-2 is due to viral antigenic mimicry with human tissue?
If the answer is yes, then we may face an increase in the rates of autoimmune disease in the future, because any factor that causes chronic inflammation in the body can potentially induce autoimmune disease.'
All the more need for something to knock this virus on the head at the earliest possible moment.
Research/trial data from SNG's work with SNG001 for MS (an autoimmune disease) and COPD together with the current trials with Covid19 patients in hospital and at home should give them a very broad insight into SNG001's cell protection abilities and disease progression prevention.
'Tom Wilkinson, a professor of respiratory medicine at the University of Southampton, said, “We are hoping that the drug will increase the rate of recovery from infection, that it will increase the protection in the bit of the lungs that are not infected yet and will reduce the number of patients that decline significantly and require intubation and ventilation.”
https://www.pharmaceutical-technology.com/comment/synairgen-sng001-covid-19-trials/